ArticlePloS one2017
Ancient genes establish stress-induced mutation as a hallmark of cancer.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 56 citations in OpenAlex.
- Cancer as an evolutionary reversal-time for a paradigm shift.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- The Multiscale Wisdom of the Body: Collective Intelligence as a Tractable Interface for Next-Generation Biomedicine.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025Review
- Stress sharing as cognitive glue for collective intelligences: A computational model of stress as a coordinator for morphogenesis.Biochemical and biophysical research communications · 2024Article
- Evolutionary screening of precision oncology biomarkers and its applications in prognostic model construction.iScience · 2024Article
- Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins.Genome biology · 2024Article
- Cell-in-cell phenomena across the tree of life.Scientific reports · 2024Article
- On the gene expression landscape of cancer.PloS one · 2023Article
- The evolutionary cancer genome theory and its reasoning.Genetics in medicine open · 2023Review
- Pan-cancer surveys indicate cell cycle-related roles of primate-specific genes in tumors and embryonic cerebrum.Genome biology · 2022Article
- Estimating the number of available states for normal and tumor tissues in gene expression space.Biophysical reports · 2022Article
- A one-dimensional parameter-free model for carcinogenesis in gene expression space.Scientific reports · 2022Article
- Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer.Frontiers in genetics · 2022Article
- Neural is Fundamental: Neural Stemness as the Ground State of Cell Tumorigenicity and Differentiation Potential.Stem cell reviews and reports · 2022Review
- Struggle within: evolution and ecology of somatic cell populations.Cellular and molecular life sciences : CMLS · 2021Review
- Reverting to single-cell biology: The predictions of the atavism theory of cancer.Progress in biophysics and molecular biology · 2021Article
- Cancer progression as a sequence of atavistic reversions.BioEssays : news and reviews in molecular, cellular and developmental biology · 2021Article
- Stepping From Modeling Cancer Plasticity to the Philosophy of Cancer.Frontiers in genetics · 2020Article
- Cell plasticity in cancer cell populations.F1000Research · 2020Review
- Unexpected Discoveries Should Be Reconsidered in Science-A Look to the Past?International journal of molecular sciences · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is sometimes depicted as a reversion to single cell behavior in cells adapted to live in a multicellular assembly. If this is the case, one would expect that mutation in cancer disrupts functional mechanisms that suppress cell-level traits detrimental to multicellularity. Such mechanisms should have evolved with or after the emergence of multicellularity. This leads to two related, but distinct hypotheses: 1) Somatic mutations in cancer will occur in genes that are younger than the emergence of multicellularity (1000 million years [MY]); and 2) genes that are frequently mutated in cancer and whose mutations are functionally important for the emergence of the cancer phenotype evolved within the past 1000 million years, and thus would exhibit an age distribution that is skewed to younger genes. In order to investigate these hypotheses we estimated the evolutionary ages of all human genes and then studied the probability of mutation and their biological function in relation to their age and genomic location for both normal germline and cancer contexts. We observed that under a model of uniform random mutation across the genome, controlled for gene size, genes less than 500 MY were more frequently mutated in both cases. Paradoxically, causal genes, defined in the COSMIC Cancer Gene Census, were depleted in this age group. When we used functional enrichment analysis to explain this unexpected result we discovered that COSMIC genes with recessive disease phenotypes were enriched for DNA repair and cell cycle control. The non-mutated genes in these pathways are orthologous to those underlying stress-induced mutation in bacteria, which results in the clustering of single nucleotide variations. COSMIC genes were less common in regions where the probability of observing mutational clusters is high, although they are approximately 2-fold more likely to harbor mutational clusters compared to other human genes. Our results suggest this ancient mutational response to stress that evolved among prokaryotes was co-opted to maintain diversity in the germline and immune system, while the original phenotype is restored in cancer. Reversion to a stress-induced mutational response is a hallmark of cancer that allows for effectively searching "protected" genome space where genes causally implicated in cancer are located and underlies the high adaptive potential and concomitant therapeutic resistance that is characteristic of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.